Prot #GO28141: A Phase III, Double-Blind, Placebo-Controlled Study Of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAFv600-Mutation Positive Patients with Unresectable Locally Advanced or Metastatic Melanoma